Perrigo Company has settled its Hatch-Waxman litigation relating to Nascobal® (Cyanocobalamin) Nasal Spray brought by Endo Pharmaceuticals Inc. Terms of the settlement are confidential.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Annual market sales for the 12-months ending June 2019 were $90 million as measured by IQVIA™.
Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This settlement is another example of our long-term commitment and investments in our extended topicals strategy. Our R&D, operations and legal teams continue to work diligently and relentlessly to introduce new generic products that provide savings to patients and healthcare systems."